search
Back to results

An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension

Primary Purpose

Systolic Hypertension

Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
LCZ696
Valsartan
AHU377
Placebo
Sponsored by
Novartis Pharmaceuticals
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Systolic Hypertension focused on measuring hypertension, blood pressure, LCZ696, dual-acting, neprilysin, nep inhibitor, vasopeptidase, angiotensin receptor, angiotensin receptor neprilysin inhibitor (ARNi)

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Written informed consent must be obtained before any assessment is performed. Patients with mild-to-moderate systolic hypertension, untreated or currently taking antihypertensive therapy.
  • Ability to communicate and comply with all study requirements and demonstrate good medication compliance (≥ 80% compliance rate) during the run-in period.

Exclusion Criteria:

  • Severe hypertension
  • History of angioedema, drug-related or otherwise, as reported by the patient.
  • Pregnant or nursing (lactating) women.
  • Women of child-bearing potential (WOCBP), UNLESS they are using adequate birth control methods.
  • History or evidence of a secondary form of hypertension.
  • Other protocol-defined inclusion/exclusion criteria may apply

Sites / Locations

  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

VAL + AHU 400 mg

VAL + AHU 200 mg

VAL + AHU 100 mg

VAL + AHU 50 mg

VAL 320 mg

LCZ 400 mg

Placebo

Arm Description

Participants were started with AHU377 100 mg + valsartan 160 mg every day (qd) for 1 week, then were uptitrated to AHU377 200 mg + valsartan 320 mg qd for another week, and then were uptitrated to AHU377 400 mg + valsartan 320 mg for the remaining 6 weeks.

Participants were started with AHU377 100 mg + valsartan 160 mg qd for 1 week and then were uptitrated to AHU377 200 mg + valsartan 320 mg qd for the remaining 7 weeks.

Participants were started with AHU377 50 mg + valsartan 160 mg qd for 1 week and then were uptitrated to AHU377 100 mg + valsartan 320 mg for the remaining 7 weeks.

Participants were started with AHU377 50 mg + valsartan 160 mg qd for 1 week and then were uptitrated to AHU377 50 mg + valartan 320 mg qd for the remaining 7 weeks.

Participants were started with valsartan 160 mg qd for 1 week and then were uptitrated to valsartan 320 mg qd for the remaining 7 weeks.

Participants were started with LCZ696 200 mg qd for 1 week and then were uptitrated to LCZ696 400 mg qd for the remaining 7 weeks.

Participants received matching placebo to LCZ696, AHU377 and valsartan for 8 weeks.

Outcomes

Primary Outcome Measures

Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)
Sitting BP measurements were performed at trough (23-26 hours post-morning dose). A negative change from baseline indicates improvement.

Secondary Outcome Measures

Change From Baseline in Mean Diastolic Blood Pressure (msDBP)
Sitting BP measurements were performed at trough (23-26 hours post-morning dose). A negative change from baseline indicates improvement.
Change From Baseline in Mean 24 Hour Ambulatory SBP (maSBP) and Mean 24 Hour Ambulatory DBP (maDBP)
Twenty four hour ABPM was performed twice duirng the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. A negative change from baseline indicates improvement.
Change From Baseline in Daytime maSBP and maDBP
Twenty four hour ABPM was performed twice during the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. A negative change from baseline indicates improvement.
Change From Baseline in Nighttime maSBP and maDBP
Twenty four hour ABPM was performed twice duirng the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. A negative change from baseline indicates improvement.
Change From Baseline in Mean Sitting Pulse Pressure
Pulse rate measurements were performed. A negative change from baseline indicates improvement.
Change From Baseline in Mean Ambulatory Pulse Pressure
Pulse rate measurements were performed. A negative change from baseline indicates improvement.
Change From Baseline in maSBP and maDBP in Dippers
Twenty four hour ABPM was performed twice during the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. Dippers were defined as participants who showed a decrease of at least 10% in maSBP during the night (10pm-6am) compared with the daytime level. A negative change from baseline indicates improvement.
Change From Baseline in maSBP and maDBP in Non-dippers
Twenty four hour ABPM was performed twice duirng the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. Dippers were defined as participants who showed a decrease of at least 10% in maSBP during the night (10pm-6am) compared with the daytime level. A negative change from baseline indicates improvement.
Change From Baseline in msSBP and msDBP in Participants < 65 Years of Age
Sitting BP measurements were performed at trough (23-26 hours post-morning dose). A negative change from baseline indicates improvement.
Change From Baseline in msSBP and msDBP in Participants >= 65 Years of Age
Sitting BP measurements were performed at trough (23-26 hours post-morning dose). A negative change from baseline indicates improvement.
Change From Baseline in maSBP and maDBP in Participants < 65 Years of Age
Twenty four hour ABPM was performed twice duirng the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. A negative change from baseline indicates improvement.
Change From Baseline in maSBP and maDBP in Participants >= 65 Years of Age
Twenty four hour ABPM was performed twice duirng the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. A negative change from baseline indicates improvement.
Number of Participants Who Achieved Blood Pressure Control and Blood Pressure Response
Sitting BP measurements were performed at trough (23-26 hours post-morning dose). Blood pressure control was defined as msSBP/MSDBP < 140/90 mmHg. Blood pressure response in msSBP was defined as <140 mmHg or a reduction >= 20mmHg from baseline. Blood pressure response in msDBP was defined as < 90 mmHg or a reduction >= 10 mmHg from baseline.
Number of Participants With Adverse Events, Serious Adverse Events and Death
Adverse event monitoring was conducted throughout the study.

Full Information

First Posted
January 20, 2011
Last Updated
December 22, 2015
Sponsor
Novartis Pharmaceuticals
search

1. Study Identification

Unique Protocol Identification Number
NCT01281306
Brief Title
An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension
Official Title
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg After 8 Week Treatment in Patients With Mild-to-moderate Systolic Hypertension
Study Type
Interventional

2. Study Status

Record Verification Date
December 2015
Overall Recruitment Status
Completed
Study Start Date
January 2011 (undefined)
Primary Completion Date
December 2011 (Actual)
Study Completion Date
December 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novartis Pharmaceuticals

4. Oversight

5. Study Description

Brief Summary
The purpose of the study is to evaluate dose response of blood pressure lowering for 4 doses of AHU377, given once daily (50 mg, 100 mg, 200 mg and 400 mg) in combination with a fixed dose of valsartan (320 mg).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Systolic Hypertension
Keywords
hypertension, blood pressure, LCZ696, dual-acting, neprilysin, nep inhibitor, vasopeptidase, angiotensin receptor, angiotensin receptor neprilysin inhibitor (ARNi)

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
910 (Actual)

8. Arms, Groups, and Interventions

Arm Title
VAL + AHU 400 mg
Arm Type
Experimental
Arm Description
Participants were started with AHU377 100 mg + valsartan 160 mg every day (qd) for 1 week, then were uptitrated to AHU377 200 mg + valsartan 320 mg qd for another week, and then were uptitrated to AHU377 400 mg + valsartan 320 mg for the remaining 6 weeks.
Arm Title
VAL + AHU 200 mg
Arm Type
Experimental
Arm Description
Participants were started with AHU377 100 mg + valsartan 160 mg qd for 1 week and then were uptitrated to AHU377 200 mg + valsartan 320 mg qd for the remaining 7 weeks.
Arm Title
VAL + AHU 100 mg
Arm Type
Experimental
Arm Description
Participants were started with AHU377 50 mg + valsartan 160 mg qd for 1 week and then were uptitrated to AHU377 100 mg + valsartan 320 mg for the remaining 7 weeks.
Arm Title
VAL + AHU 50 mg
Arm Type
Experimental
Arm Description
Participants were started with AHU377 50 mg + valsartan 160 mg qd for 1 week and then were uptitrated to AHU377 50 mg + valartan 320 mg qd for the remaining 7 weeks.
Arm Title
VAL 320 mg
Arm Type
Experimental
Arm Description
Participants were started with valsartan 160 mg qd for 1 week and then were uptitrated to valsartan 320 mg qd for the remaining 7 weeks.
Arm Title
LCZ 400 mg
Arm Type
Experimental
Arm Description
Participants were started with LCZ696 200 mg qd for 1 week and then were uptitrated to LCZ696 400 mg qd for the remaining 7 weeks.
Arm Title
Placebo
Arm Type
Experimental
Arm Description
Participants received matching placebo to LCZ696, AHU377 and valsartan for 8 weeks.
Intervention Type
Drug
Intervention Name(s)
LCZ696
Intervention Description
LCZ696 was supplied as tablets in blister cards in 100 mg strengths.
Intervention Type
Drug
Intervention Name(s)
Valsartan
Intervention Description
Valsartan was supplied as tablets in blister cards in 160 mg and 320 mg strengths.
Intervention Type
Drug
Intervention Name(s)
AHU377
Intervention Description
AHU377 was supplied in tablets in blister cards in 50 mg and 100 mg strengths.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo was supplied as tablets in blister cards.
Primary Outcome Measure Information:
Title
Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)
Description
Sitting BP measurements were performed at trough (23-26 hours post-morning dose). A negative change from baseline indicates improvement.
Time Frame
Baseline, 8 weeks
Secondary Outcome Measure Information:
Title
Change From Baseline in Mean Diastolic Blood Pressure (msDBP)
Description
Sitting BP measurements were performed at trough (23-26 hours post-morning dose). A negative change from baseline indicates improvement.
Time Frame
Baseline, 8 weeks
Title
Change From Baseline in Mean 24 Hour Ambulatory SBP (maSBP) and Mean 24 Hour Ambulatory DBP (maDBP)
Description
Twenty four hour ABPM was performed twice duirng the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. A negative change from baseline indicates improvement.
Time Frame
Baseline, 8 weeks
Title
Change From Baseline in Daytime maSBP and maDBP
Description
Twenty four hour ABPM was performed twice during the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. A negative change from baseline indicates improvement.
Time Frame
Baseline, 8 weeks
Title
Change From Baseline in Nighttime maSBP and maDBP
Description
Twenty four hour ABPM was performed twice duirng the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. A negative change from baseline indicates improvement.
Time Frame
Baseline and 8 weeks
Title
Change From Baseline in Mean Sitting Pulse Pressure
Description
Pulse rate measurements were performed. A negative change from baseline indicates improvement.
Time Frame
Baseline, 8 weeks
Title
Change From Baseline in Mean Ambulatory Pulse Pressure
Description
Pulse rate measurements were performed. A negative change from baseline indicates improvement.
Time Frame
Baseline, 8 weeks
Title
Change From Baseline in maSBP and maDBP in Dippers
Description
Twenty four hour ABPM was performed twice during the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. Dippers were defined as participants who showed a decrease of at least 10% in maSBP during the night (10pm-6am) compared with the daytime level. A negative change from baseline indicates improvement.
Time Frame
Baseline, 8 weeks
Title
Change From Baseline in maSBP and maDBP in Non-dippers
Description
Twenty four hour ABPM was performed twice duirng the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. Dippers were defined as participants who showed a decrease of at least 10% in maSBP during the night (10pm-6am) compared with the daytime level. A negative change from baseline indicates improvement.
Time Frame
Baseline, 8 weeks
Title
Change From Baseline in msSBP and msDBP in Participants < 65 Years of Age
Description
Sitting BP measurements were performed at trough (23-26 hours post-morning dose). A negative change from baseline indicates improvement.
Time Frame
Baseline, 8 weeks
Title
Change From Baseline in msSBP and msDBP in Participants >= 65 Years of Age
Description
Sitting BP measurements were performed at trough (23-26 hours post-morning dose). A negative change from baseline indicates improvement.
Time Frame
Baseline, 8 weeks
Title
Change From Baseline in maSBP and maDBP in Participants < 65 Years of Age
Description
Twenty four hour ABPM was performed twice duirng the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. A negative change from baseline indicates improvement.
Time Frame
Baseline, 8 weeks
Title
Change From Baseline in maSBP and maDBP in Participants >= 65 Years of Age
Description
Twenty four hour ABPM was performed twice duirng the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. A negative change from baseline indicates improvement.
Time Frame
Baseline, 8 weeks
Title
Number of Participants Who Achieved Blood Pressure Control and Blood Pressure Response
Description
Sitting BP measurements were performed at trough (23-26 hours post-morning dose). Blood pressure control was defined as msSBP/MSDBP < 140/90 mmHg. Blood pressure response in msSBP was defined as <140 mmHg or a reduction >= 20mmHg from baseline. Blood pressure response in msDBP was defined as < 90 mmHg or a reduction >= 10 mmHg from baseline.
Time Frame
8 weeks
Title
Number of Participants With Adverse Events, Serious Adverse Events and Death
Description
Adverse event monitoring was conducted throughout the study.
Time Frame
8 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Written informed consent must be obtained before any assessment is performed. Patients with mild-to-moderate systolic hypertension, untreated or currently taking antihypertensive therapy. Ability to communicate and comply with all study requirements and demonstrate good medication compliance (≥ 80% compliance rate) during the run-in period. Exclusion Criteria: Severe hypertension History of angioedema, drug-related or otherwise, as reported by the patient. Pregnant or nursing (lactating) women. Women of child-bearing potential (WOCBP), UNLESS they are using adequate birth control methods. History or evidence of a secondary form of hypertension. Other protocol-defined inclusion/exclusion criteria may apply
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Novartis Pharmaceuticals
Organizational Affiliation
Novartis Pharmaceuticals
Official's Role
Study Director
Facility Information:
Facility Name
Novartis Investigative Site
City
Clearwater
State/Province
Florida
ZIP/Postal Code
33756
Country
United States
Facility Name
Novartis Investigative Site
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60607
Country
United States
Facility Name
Novartis Investigative Site
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60610
Country
United States
Facility Name
Novartis Investigative Site
City
Metairie
State/Province
Louisiana
ZIP/Postal Code
70006
Country
United States
Facility Name
Novartis Investigative Site
City
Belzoni
State/Province
Mississippi
ZIP/Postal Code
39038
Country
United States
Facility Name
Novartis Investigative Site
City
Jackson
State/Province
Mississippi
ZIP/Postal Code
39202
Country
United States
Facility Name
Novartis Investigative Site
City
Jackson
State/Province
Mississippi
ZIP/Postal Code
39209
Country
United States
Facility Name
Novartis Investigative Site
City
St. Louis
State/Province
Missouri
ZIP/Postal Code
63031
Country
United States
Facility Name
Novartis Investigative Site
City
St. Louis
State/Province
Missouri
ZIP/Postal Code
63141
Country
United States
Facility Name
Novartis Investigative Site
City
Henderson
State/Province
Nevada
ZIP/Postal Code
89014
Country
United States
Facility Name
Novartis Investigative Site
City
Las Vegas
State/Province
Nevada
ZIP/Postal Code
89119
Country
United States
Facility Name
Novartis Investigative Site
City
Buffalo
State/Province
New York
ZIP/Postal Code
14215
Country
United States
Facility Name
Novartis Investigative Site
City
Charlotte
State/Province
North Carolina
ZIP/Postal Code
28277
Country
United States
Facility Name
Novartis Investigative Site
City
Greensboro
State/Province
North Carolina
ZIP/Postal Code
27401
Country
United States
Facility Name
Novartis Investigative Site
City
Greensboro
State/Province
North Carolina
ZIP/Postal Code
27408
Country
United States
Facility Name
Novartis Investigative Site
City
Shelby
State/Province
North Carolina
ZIP/Postal Code
28152
Country
United States
Facility Name
Novartis Investigative Site
City
Erie
State/Province
Pennsylvania
ZIP/Postal Code
16509
Country
United States
Facility Name
Novartis Investigative Site
City
Bryan
State/Province
Texas
ZIP/Postal Code
77802
Country
United States
Facility Name
Novartis Investigative Site
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Name
Novartis Investigative Site
City
Caba
State/Province
Buenos Aires
ZIP/Postal Code
C1440AAD
Country
Argentina
Facility Name
Novartis Investigative Site
City
Lanus
State/Province
Buenos Aires
ZIP/Postal Code
B8000XAV
Country
Argentina
Facility Name
Novartis Investigative Site
City
Caba
State/Province
Capital Federal
ZIP/Postal Code
C1179AAB
Country
Argentina
Facility Name
Novartis Investigative Site
City
Rosario
State/Province
Santa Fe
ZIP/Postal Code
S2000AII
Country
Argentina
Facility Name
Novartis Investigative Site
City
Rosario
State/Province
Santa Fe
ZIP/Postal Code
S200CXP
Country
Argentina
Facility Name
Novartis Investigative Site
City
San Miguel de Tucuman
State/Province
Tucuman
ZIP/Postal Code
T4000EBR
Country
Argentina
Facility Name
Novartis Investigative Site
City
Buenos aires
ZIP/Postal Code
C1120AAC
Country
Argentina
Facility Name
Novartis Investigative Site
City
Cordoba
ZIP/Postal Code
X5003DCP
Country
Argentina
Facility Name
Novartis Investigative Site
City
Corrientes
ZIP/Postal Code
W3400
Country
Argentina
Facility Name
Novartis Investigative Site
City
Mount Pearl
State/Province
Newfoundland and Labrador
ZIP/Postal Code
A1N 1W7
Country
Canada
Facility Name
Novartis Investigative Site
City
Mirabel
State/Province
Quebec
ZIP/Postal Code
J7J 2K8
Country
Canada
Facility Name
Novartis Investigative Site
City
Ste-Foy
State/Province
Quebec
ZIP/Postal Code
G1V 4G2
Country
Canada
Facility Name
Novartis Investigative Site
City
Budapest
ZIP/Postal Code
1045
Country
Hungary
Facility Name
Novartis Investigative Site
City
Budapest
ZIP/Postal Code
1136
Country
Hungary
Facility Name
Novartis Investigative Site
City
Csongrad
ZIP/Postal Code
6640
Country
Hungary
Facility Name
Novartis Investigative Site
City
Erd
ZIP/Postal Code
H-2030
Country
Hungary
Facility Name
Novartis Investigative Site
City
Miskolc
ZIP/Postal Code
3525
Country
Hungary
Facility Name
Novartis Investigative Site
City
Miskolc
ZIP/Postal Code
3530
Country
Hungary
Facility Name
Novartis Investigative Site
City
Nyiregyháza
ZIP/Postal Code
4400
Country
Hungary
Facility Name
Novartis Investigative Site
City
Szeged
ZIP/Postal Code
H-6720
Country
Hungary
Facility Name
Novartis Investigative Site
City
Torokbalint
ZIP/Postal Code
2045
Country
Hungary
Facility Name
Novartis Investigative Site
City
Vishakhapatnam
State/Province
Andhra Pradesh
ZIP/Postal Code
530002
Country
India
Facility Name
Novartis Investigative Site
City
Ahmedabad
State/Province
Gujarat
ZIP/Postal Code
380 051
Country
India
Facility Name
Novartis Investigative Site
City
Nashik
State/Province
Maharashtra
ZIP/Postal Code
422 005
Country
India
Facility Name
Novartis Investigative Site
City
Nashik
State/Province
Maharashtra
ZIP/Postal Code
422005
Country
India
Facility Name
Novartis Investigative Site
City
Pune
State/Province
Maharashtra
ZIP/Postal Code
411005
Country
India
Facility Name
Novartis Investigative Site
City
Ludhiana
State/Province
Punjab
ZIP/Postal Code
141002
Country
India
Facility Name
Novartis Investigative Site
City
Jaipur
State/Province
Rajasthan
ZIP/Postal Code
302016
Country
India
Facility Name
Novartis Investigative Site
City
Lucknow
State/Province
Uttar Pradesh
ZIP/Postal Code
226003
Country
India
Facility Name
Novartis Investigative Site
City
Lucknow
State/Province
Uttar Pradesh
ZIP/Postal Code
226005
Country
India
Facility Name
Novartis Investigative Site
City
Bucheon
State/Province
Gyeonggi-do
ZIP/Postal Code
424-717
Country
Korea, Republic of
Facility Name
Novartis Investigative Site
City
Goyang
State/Province
Gyeonggi-do
ZIP/Postal Code
411-706
Country
Korea, Republic of
Facility Name
Novartis Investigative Site
City
Uijeongbu-Si
State/Province
Gyeonggi-do
ZIP/Postal Code
480-717
Country
Korea, Republic of
Facility Name
Novartis Investigative Site
City
Seoul
State/Province
Korea
ZIP/Postal Code
05505
Country
Korea, Republic of
Facility Name
Novartis Investigative Site
City
Seoul
State/Province
Korea
ZIP/Postal Code
137-701
Country
Korea, Republic of
Facility Name
Novartis Investigative Site
City
Seoul
State/Province
Korea
ZIP/Postal Code
152-703
Country
Korea, Republic of
Facility Name
Novartis Investigative Site
City
Koyang
State/Province
Kyunggi
ZIP/Postal Code
410-719
Country
Korea, Republic of
Facility Name
Novartis Investigative Site
City
Seoul
ZIP/Postal Code
140-743
Country
Korea, Republic of
Facility Name
Novartis Investigative Site
City
Seoul
ZIP/Postal Code
150-713
Country
Korea, Republic of
Facility Name
Novartis Investigative Site
City
Seoul
ZIP/Postal Code
150-950
Country
Korea, Republic of
Facility Name
Novartis Investigative Site
City
Bucharest
State/Province
District 1
ZIP/Postal Code
011422
Country
Romania
Facility Name
Novartis Investigative Site
City
Bucharest
State/Province
District 1
ZIP/Postal Code
012064
Country
Romania
Facility Name
Novartis Investigative Site
City
Bucharest
State/Province
District 1
Country
Romania
Facility Name
Novartis Investigative Site
City
Bucharest
State/Province
District 2
ZIP/Postal Code
021705
Country
Romania
Facility Name
Novartis Investigative Site
City
Oradea
State/Province
Jud. Bihor
ZIP/Postal Code
410032
Country
Romania
Facility Name
Novartis Investigative Site
City
Craiova
State/Province
Jud. Dolj
ZIP/Postal Code
200147
Country
Romania
Facility Name
Novartis Investigative Site
City
Bucharest
ZIP/Postal Code
060011
Country
Romania
Facility Name
Novartis Investigative Site
City
Nitra
State/Province
Slovak Republic
ZIP/Postal Code
949 01
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Presov
State/Province
Slovak Republic
ZIP/Postal Code
08001
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Bratislava
ZIP/Postal Code
831 06
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Liptovsky Mikulas
ZIP/Postal Code
031 01
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Nitra
ZIP/Postal Code
949 01
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Nitra
ZIP/Postal Code
94901
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Nove Zamky
ZIP/Postal Code
940 01
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Partizanske
ZIP/Postal Code
958 01
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Presov
ZIP/Postal Code
080 01
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Presov
ZIP/Postal Code
081 01
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Ruzomberok
ZIP/Postal Code
034 26
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Sala
ZIP/Postal Code
927 03
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Sered
ZIP/Postal Code
926 00
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Zvolen
ZIP/Postal Code
960 01
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Granada
State/Province
Andalucia
ZIP/Postal Code
18012
Country
Spain
Facility Name
Novartis Investigative Site
City
Sevilla
State/Province
Andalucia
ZIP/Postal Code
41009
Country
Spain
Facility Name
Novartis Investigative Site
City
Badalona
State/Province
Cataluña
ZIP/Postal Code
08914
Country
Spain
Facility Name
Novartis Investigative Site
City
Centelles
State/Province
Cataluña
ZIP/Postal Code
08540
Country
Spain
Facility Name
Novartis Investigative Site
City
Tarragona
State/Province
Cataluña
ZIP/Postal Code
43350
Country
Spain
Facility Name
Novartis Investigative Site
City
Alicante
State/Province
Comunidad Valenciana
ZIP/Postal Code
03004
Country
Spain
Facility Name
Novartis Investigative Site
City
Alzira
State/Province
Comunidad Valenciana
ZIP/Postal Code
46600
Country
Spain
Facility Name
Novartis Investigative Site
City
Santiago de Compostela
State/Province
Galicia
ZIP/Postal Code
15706
Country
Spain
Facility Name
Novartis Investigative Site
City
Barcelona
Country
Spain
Facility Name
Novartis Investigative Site
City
Madrid
ZIP/Postal Code
28046
Country
Spain

12. IPD Sharing Statement

Learn more about this trial

An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension

We'll reach out to this number within 24 hrs